Press Releases

31/10/2019 Biom’up announces opening of a court-supervised reorganization procedure (redressement judiciaire) pdf
07/10/2019 Biom’up announces the approval of HEMOBLASTTM Bellows and its laparoscopic applicator in Australia pdf
30/09/2019 Approval of 2019 H1 interim results postponed: Board of Directors pursues review of options available to the Company pdf
19/09/2019 Biom’up strengthens management team
14/08/2019 New Publication Highlights Application of HEMOBLAST™ Bellows in Cardiovascular Surgery pdf
07/08/2019 Biom’up issues a new tranche of €5 million from the credit line granted by Athyrium pdf
10/07/2019 Biom’up Provides Business Update for the First Half of 2019 and confirms its Revenue Guidance for the year pdf
05/31/2019 Industry Veteran Dr. Jan Ohrstrom takes on Executive Leadership of Biom’up pdf
05/21/2019 Biom’up to Present at the RBC Capital Markets Global Healthcare Conference on Tuesday May 21, 2019 in New York City pdf
05/20/2019 Biom’up provides 2019 guidance for HEMOBLASTTM Bellows global sales pdf
04/30/2019 Biom’up reports 2018 full-year results and confirms strong commercial uptake in Q1 2019 pdf
04/24/2019 Biom’up granted FDA IDE approval for HEMOSNOW™ pdf
04/15/2019 Biom’up announces first US sales in laparoscopy for HEMOBLASTTM Bellows and the signing of an exclusive distribution agreement for HEMOBLASTTM Bellows in Australia pdf
04/12/2019 Biom’up Notice of 2018 Year End results pdf
01/31/2019 Biom’up appoints George Makhoul as Chief Commercial Officer (USA) pdf
01/30/2019 Biom’up HEMOBLASTTM Bellows full pivotal trial results published in Journal of Cardiac Surgery pdf
01/22/2019 Biom’up granted FDA approval for its HEMOBLASTTM Bellows Laparoscopic Applicator pdf
01/07/2019 Achievement of two major development milestones pdf
12/31/2018 Biom’up raises €3 million from the €10 million credit line granted in March 2018 by Athyrium pdf
12/06/2018 Biom’up successfully closes a €7.67 million private placement financing pdf
12/05/2018 Biom’up launches a private placement financing of a minimum of €7 million pdf
11/28/2018 Biom’up sees a strong commercial uptake in HEMOBLASTTM Bellows in the US and Europe pdf
11/08/2018 Biom’up announces completion of the 2018 scale-up of its manufacturing facility to meet commercial demand for HEMOBLASTTM Bellows pdf
10/18/2018 Reinforcement of management’s participation in the Company’s share capital pdf
10/16/2018 Biom’up announces a first distribution agreement in Europe and the filing of a reimbursement dossier with Australian health authorities pdf
09/13/2018 H1 2018 results on track with the company’s business plan pdf
09/04/2018 Biom’up completes its Board of Directors with the nomination of Dr. Peter Byloos to support its international growth pdf
07/25/2018 Biom’up present at the 8th Strategic Council of Health Industries hosted by France’s Prime Minister pdf
07/12/2018 Biom’up obtains CE Mark for its HEMOBLASTTM Bellows Laparoscopic Applicator pdf

Biom’up announces first sales of HEMOBLASTTM Bellows in the United States and the nomination to its board of directors of an independent director and an observer to support the company’s growth

05/02/2018 Biom’up finalizes U.S. commercial organization to support U.S. launch of HEMOBLASTTM Bellows pdf
04/24/2018 Biom’up has trained 200 surgeons in the US and in Europe ahead of HEMOBLAST Bellows™ launch pdf
04/16/2018 Biom'up reports 2017 full-year results  and provides corporate update pdf
04/03/2018 Biom’up and Athyrium close first tranche of bond financing for €25 million with stock warrants attached pdf
03/26/2018 Biom’up Appoints Thierry Darnis as Global Vice President, Manufacturing & Engineering pdf

Biom’up announces the construction of a new production plant and the creation of 150 jobs in Lyon Metropole

02/20/2018 Biom'up completes the first of its financing operations for a total amount of more than €40 million pdf
02/14/2018 Biom’up announces a financing targeting a total of €43m pdf
01/22/2018 Summary of Biom'Up's liquidity contract with CM-CIC Market Solutions (in French) pdf

12/18/2017 Biom’up receives FDA marketing approval for HEMOBLASTTM Bellows, its flagship product pdf
12/13/2017 Biom’up to be included in the Euronext’s CAC® Small, CAC® Mid & Small and CAC® All-Tradable indexes pdf
12/06/2017 Biom’up appoints Cécile Ferracci as Global Vice President Marketing pdf
11/09/2017 Biom’up confirms the success of its IPO. Over-allotment option partially exercised pdf
10/27/2017 Biom’up provides regulatory update regarding HEMOBLAST™ Bellows pdf
10/11/2017 Biom’up announces the success of its IPO, raising close to €38.1 million on Euronext Paris pdf
09/26/2017 Biom’up launches its IPO on the Euronext regulated market in Paris pdf
09/12/2017 Filing of the document de Base pdf